ONC (BeOne Medicines) Inventory Turnover: 0.26 (As of Mar. 2026)

What is BeOne Medicines Inventory Turnover?

BeOne Medicines ONC +2.38% 78 Inventory Turnover is 0.26 as of Mar. 2026. GuruFocus rates ONC with a GF Score™ of 78/100 and a GF Value™ of $367.06 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. BeOne Medicines's Cost of Goods Sold for the three months ended in Mar. 2026 was $167 Mil. BeOne Medicines's Average Total Inventories for the quarter that ended in Mar. 2026 was $645 Mil. BeOne Medicines's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.26.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. BeOne Medicines's Days Inventory for the three months ended in Mar. 2026 was 351.93.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BeOne Medicines's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.43.

BeOne Medicines (NAS:ONC) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BeOne Medicines's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2026 )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
	=	644.9085	/	167.215	*	365 / 4
	=	351.93

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BeOne Medicines's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	644.9085	/	1513.438
	=	0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

BeOne Medicines Inventory Turnover Related Terms

BeOne Medicines Inventory Turnover Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Inventory Turnover can be seen below:

BeOne Medicines Inventory Turnover Chart

BeOne Medicines Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Inventory Turnover

Get a 7-Day Free Trial

0.99

1.09

1.30

1.21

BeOne Medicines Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventory Turnover	Get a 7-Day Free Trial															0.33	0.33	0.38	0.25	0.26

78GF Score

BeOne Medicines Ltd ONC

Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BeOne Medicines Inventory Turnover Calculation

BeOne Medicines's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

	Inventory Turnover (A: Dec. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2025 )	/ (	(Total Inventories (A: Dec. 2024 )	+	Total Inventories (A: Dec. 2025 ))	/	count )
=	668.54	/ (	(494.986	+	608.227)	/	2 )
=	668.54	/	551.6065
=	1.21

BeOne Medicines's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

	Inventory Turnover (Q: Mar. 2026 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2026 )	/ (	(Total Inventories (Q: Dec. 2025 )	+	Total Inventories (Q: Mar. 2026 ))	/	count )
=	167.215	/ (	(608.227	+	681.59)	/	2 )
=	167.215	/	644.9085
=	0.26

Frequently Asked Questions Learn more about Inventory Turnover →

What does a Inventory Turnover of 0.26 mean?

BeOne Medicines (ONC) has a Inventory Turnover of 0.26 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on BeOne Medicines and its competitors.

Is BeOne Medicines' Inventory Turnover too high?

BeOne Medicines' current Inventory Turnover is 0.26. Overall, BeOne Medicines has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does BeOne Medicines' Inventory Turnover compare to MRNA and RPRX?

BeOne Medicines' Inventory Turnover of 0.26 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventory Turnover for a Biotechnology company?

A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventory Turnover mean?

A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Inventory Turnover is 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BeOne Medicines stock overvalued right now?

Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $367.06, compared to a current price of $297.65 — trading 18.9% below its estimated fair value. The current Inventory Turnover is 0.26. BeOne Medicines' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventory Turnover calculated?

Inventory Turnover is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Inventory Turnover is 0.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $297.65 is trading 18.9% below its estimated GF Value™ of $367.06. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for ONC:

Inventory Turnover: 0.26
GF Value™: $367.06 vs. price of $297.65 (18.9% below fair value)
GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Industry Healthcare Biotechnology

Comparable Companies MRNA RPRX ROIV BNTX INCY INSM RVMD ALNY ASND JAZZ VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ASX:CSL XKRX:068270 HKSE:02269 HKSE:01801 OCSE:GMAB

Other Exchanges BEIGF:USA 06160:Hong Kong 49BA:Germany 688235:China B1ME34:Brazil

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051

Website https://www.beonemedicines.com

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

78GF Score

Get the complete analysis for ONC

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$297.65

Price

$367.06

GF Value

View ONC Analysis

See Inventory Turnover data for all stocks →